Keywords: UK, NICE, Celgene, Thalidomide, Janssen, Velcade, Johnson & Johnson, Multipel myeloma
UK’s NICE recommends Celgene’s Thalidomide and Janssen’s Velcade for multiple myeloma
Article | 27 July 2011
UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has published a final guidance recommending National Health ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
